secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fresh Tracks Therapeutics, Inc. (—)
CIK:        0000819050
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001628280-24-009548
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fresh Tracks Therapeutics terminates exclusive license agreement with Carna Biosciences for STING inhibitors
--------------------------------------------------------------------------------

- Terminated Exclusive License Agreement with Carna Biosciences effective March 1, 2024, returning worldwide rights to STING inhibitors.
- Initial $2.0M cash payment already made; all future contingent milestone payments (up to $258M) and royalties (up to 10%) are terminated.
- Survival of certain provisions: indemnification, confidentiality, dispute resolution, audit rights, record retention, taxes, and ownership of inventions.
- Company had acquired exclusive rights to research, develop, and commercialize Carna's STING inhibitor portfolio in February 2022.
- No new financial terms or costs disclosed for the termination; the agreement is nullified except for surviving clauses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/819050/000162828024009548/0001628280-24-009548-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/819050/000162828024009548/frtx-20240305.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-009548

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer